Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website


Novartis reported $29.15B in Debt for its fiscal quarter ending in March of 2023.

Debt Change
Alcon AG ALC:SW USD 5.11B 39M
Almirall SA ALM:SM EUR 403.88M 12.53M
Amgen AMGN:US USD 61.6B 22.65B
Artemis Alpha ATS:LN GBP 0 0
AstraZeneca AZN:LN USD 31.5B 2.27B
Bayer BAYN:GR EUR 43.3B 1.65B
Biogen BIIB:US USD 6.28B 1.7M
Bristol-Myers Squibb BMY:US USD 37.83B 1.49B
Eli Lilly LLY:US USD 18.88B 2.64B
Fresenius FRE:GR EUR 34.22B 6.46B
Galapagos GLPG:NA EUR 16M 5.9M
Genmab GEN:DC DKK 829M 232M
GlaxoSmithKline GSK:LN GBP 20.9B 82M
Hikma Pharmaceutical HIK:LN USD 1.28B 268M
J&J JNJ:US USD 52.91B 13.25B
Lonza Group LONN:SW CHF 2.23B 171M
Merck MRK:GR EUR 10.64B 246M
Novartis NOVN:VX USD 29.15B 1.24B
Novartis NVS:US USD 29.15B 1.24B
Orion ORNBV:FH EUR 210.6M 3.4M
Recordati REC:IM EUR 1.58B 135.68M
Regeneron Pharmaceuticals REGN:US USD 2.7B 400K
Roche Holding ROG:VX CHF 25.35B 2.4B